![]() |
市場調查報告書
商品編碼
1419142
機器人輔助手術系統市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍:按產品類型、應用、最終用戶和地理位置Robotic Assisted Surgery Systems Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type, Application, End User, and Geography |
機器人輔助手術系統市場預計將從2022年的78.31億美元成長到2030年的238.16億美元;預計2022年至2030年CAGR為14.9%。
機器人輔助手術系統市場包括越來越多技術先進的手術平台,這些平台整合了機器人、影像和導航系統,以幫助外科醫生以更高的精度和控制執行微創手術。這些系統旨在增強手術能力、改善患者治療效果並最大限度地減少傳統手術技術的侵入性。機器人輔助手術系統具有一系列優勢,包括增強的靈活性、3D可視化和震顫過濾,使外科醫生能夠以更高的準確性和可操作性執行複雜的手術。這些系統通常使外科醫生能夠進入難以到達的解剖區域,從而減少創傷並加快患者康復時間。此外,眾所周知,機器人技術在手術中的整合可以最大限度地降低併發症的風險,降低輸血的需求,並最終有助於改善術後結果。
慢性病盛行率的不斷上升推動了藥物發現服務市場的成長。
在整個預測期間,預計越來越多的利用機器人輔助操作的研究將推動市場擴張。例如,2022 年 9 月,名古屋市立大學 (NCU) 醫學科學研究生院團隊進行了一項研究,比較機器人輔助螢光鏡引導和超音波引導腎入路進行經皮腎鏡取石術。研究的結果支持了革命性機器人設備的安全性和易用性,這可能會減輕外科醫生的培訓負擔,並使更多的醫院能夠執行 PCNL 手術。這種方法使用人工智慧驅動的機器人技術,可能為類似介入手術程序的自動化打開大門,這可能會加快流程並可能降低併發症的風險。
此外,由於慢性病病例的增加以及微創手術相對開放性手術和成功率的優勢而日益普及,機器人輔助手術系統的市場正在擴大。例如,根據《印度教徒報》2022 年 8 月發布的消息稱,海得拉巴的阿波羅健康城已在印度完成了 500 多例機器人輔助婦科手術。因此,該國擴大使用微創手術(比開放手術痛苦更少),推動了市場的成長。
2022年11月,美敦力公司全資子公司India Medtronic Private Limited和德里的Venkateshwar醫院也報告了印度北部首例使用Hugo機器人輔助手術(RAS)系統完成的泌尿外科治療。
機器人輔助手術系統市場根據流程、類型、分子類型、治療領域和最終用戶進行分類。根據流程,機器人輔助手術系統市場分為目標選擇和驗證、先導化合物識別等。按類型分類,機器人輔助手術系統市場分為生物服務、醫學服務化學藥物代謝和藥物動力學。從分子類型來看,機器人輔助手術系統市場分為生物製劑和小分子。根據治療領域,機器人輔助手術系統市場分為心血管疾病、腫瘤、神經學、糖尿病、呼吸系統疾病等。此外,最終用戶部分分為製藥和生技公司、學術機構和其他。
機器人輔助手術系統市場根據產品類型、應用和最終用戶進行分類。根據產品類型,機器人輔助手術系統市場分為系統、消耗品和配件以及軟體和服務。依應用分類,機器人輔助手術系統市場分為婦科手術、心血管、神經外科、骨科手術、腹腔鏡、泌尿外科和其他應用。此外,最終使用者部分分為醫院、門診手術中心和其他最終使用者。根據地理位置,機器人輔助手術系統市場分為北美(美國、加拿大和墨西哥)、歐洲(英國、德國、法國、義大利、西班牙和歐洲其他地區)、亞太地區(中國、日本、印度、韓國、澳洲和亞太地區其他地區)、中東和非洲(阿拉伯聯合大公國、沙烏地阿拉伯、南非以及中東和非洲其他地區)以及南美洲和中美洲(巴西、阿根廷) ,以及南美洲和中美洲的其他地區)。
根據地理位置,機器人輔助手術系統市場分為北美、歐洲、亞太地區、中東和非洲以及南美洲和中美洲。北美是機器人輔助手術系統市場成長最重要的貢獻者。自動化手術器械的使用不斷增加以及美國下一代醫療系統設施的發展推動了該區域市場。此外,預計與患者人數相比,美國外科醫生和醫療專業人員的缺乏將推動機器人輔助手術系統的區域市場。此外,美國糖尿病、癌症和心血管疾病等慢性病盛行率的增加也推動了該地區對機器人輔助手術系統的需求。機器人輔助手術系統市場的主要參與者大多專注於技術開發並推出新的機器人器材以保持領先地位。此外,全球對自動化手術設備不斷成長的需求可能會促進新公司進入市場。此外,預計由於重要產業參與者透過併購、收購和合作夥伴關係取得策略性工業市場進步,競爭對手將變得更具競爭力。
疾病管制與預防中心 (CDC) 和食品藥物管理局 (FDA) 是在準備藥物發現服務市場報告時提到的幾個關鍵的主要和次要來源。
註 - 將為以下提到的地區/國家提供類似的分析
注意 - 將為以下公司列表提供類似資訊
The robotic-assisted surgery systems market is expected to grow from US$ 7.831 billion in 2022 to US$ 23.816 billion by 2030; it is anticipated to record a CAGR of 14.9% from 2022 to 2030.
The robotic-assisted surgery systems market encompasses a growing array of technologically advanced surgical platforms that integrate robotics, imaging, and navigation systems to assist surgeons in performing minimally invasive procedures with increased precision and control. These systems are designed to enhance surgical capabilities, improve patient outcomes, and minimize the invasiveness of traditional surgical techniques. Robotic-assisted surgery systems offer a range of benefits, including enhanced dexterity, three-dimensional visualization, and tremor filtration, allowing surgeons to perform complex procedures with greater accuracy and maneuverability. These systems often enable surgeons to access difficult-to-reach anatomical areas, leading to reduced trauma and faster patient recovery times. Additionally, the integration of robotic technology in surgery is known to minimize the risk of complications, lower the need for blood transfusions, and ultimately contribute to improved post-operative outcomes.
The increasing prevalence of chronic diseases drives the growth of the drug discovery services market.
Throughout the projected period, increasing research studies utilizing robotic-assisted operations are anticipated to fuel market expansion. For instance, in September 2022, a study comparing robotic-assisted fluoroscopic-guided and ultrasound-guided renal access for percutaneous nephrolithotomy was carried out by the Nagoya City University (NCU) Graduate School of Medical Sciences team. The study's findings supported the revolutionary robotic device's safety and ease of use, which may lessen the training burden on surgeons and enable more hospitals to perform PCNL procedures. This method, which uses robotics driven by artificial intelligence, may open the door to the automation of comparable interventional surgery procedures, which might speed up the process and possibly lower the risk of complications.
Additionally, the market for robotically assisted surgical systems is expanding as a result of the rise in chronic disease cases and the growing popularity of minimally invasive surgeries due to their advantages over open surgery and success rate. For example, according to news released by The Hindu in August 2022, Apollo Health City in Hyderabad has completed more than 500 robotically assisted gynecological procedures in India. As a result, the country's growing use of MIS procedures-which are less painful than open surgery-is fueling the market's rise.
In November 2022, the first urological treatment in north India to be completed with the Hugo robotic-assisted surgery (RAS) system was also reported by India Medtronic Private Limited, a wholly-owned subsidiary of Medtronic plc, and Venkateshwar Hospital in Delhi.
The robotic-assisted surgery systems market is divided on the basis of process, type, molecule type, therapeutic area, and end user. Based on the process, the robotic assisted surgery systems market is segmented into target selection and validation, hit to lead identification, and others - assay development and screening, etc. By type, the robotic assisted surgery systems market is segmented into biology services, medicinal chemistry drug metabolism, and pharmacokinetics. In terms of molecule type, the robotic assisted surgery systems market is classified as biologics and small molecules. On the basis of therapeutic areas, the robotic assisted surgery systems market is differentiated into cardiovascular diseases, oncology, neurology, diabetes, respiratory diseases, and others. Furthermore, the end-user segment is classified into Pharmaceutical and Biotechnology Companies, Academic Institutes, and Others.
The robotic assisted surgery systems market is divided on the basis of product type, application, and end user. Based on the product type, the robotic assisted surgery systems market is segmented into systems, consumables and accessories, and software and services. By application, the robotic assisted surgery systems market is segmented into gynecological surgery, cardiovascular, neurosurgery, orthopedic surgery, laparoscopy, urology, and other applications. Furthermore, the end-user segment is classified into hospitals, ambulatory surgery centers, and other end-users. Based on geography, the robotic assisted surgery systems market is divided into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Based on geography, the robotic assisted surgery systems market is divided into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America is the most significant contributor to the growth of the robotic assisted surgery systems market. The regional market is being driven by the growing use of automated surgical instruments and the growth of next-generation healthcare system facilities in the US. Furthermore, it is projected that the lack of surgeons and medical professionals in the US compared to the patient population will push the regional market for robot-assisted surgical systems. Furthermore, the need for robot-assisted surgical systems in this region is being driven by the increased prevalence of chronic diseases like diabetes, cancer, and cardiovascular disease in the US. Major players in the market for robot-assisted surgical systems mostly focus on technology development and launch new robotic instruments to keep their leading positions. Furthermore, the growing need for automated surgical equipment across the globe would likely promote the entry of new companies into the market. Furthermore, it is anticipated that rivals would become more competitive as a result of strategic industrial market advancements made by significant industry players through mergers, acquisitions, and cooperative partnerships.
Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are a few key primary and secondary sources referred to while preparing the report on the drug discovery services market.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies